AIPLA Rapid Response Webinar
AIPLA Rapid Response Webinar: USPTO Sequence Listing Rules
June 29 to 30, 2022
Location
Credits
No CLE
Registration
Standard ST.26, requiring XML formatting, will go into effect worldwide
on Friday, July 1. The United States Patent and Trademark Office (USPTO)
is adopting new rules to implement this standard as recently published
in the Federal Register. Beginning July 1, sequence listings filed
electronically in XML format must be filed via the USPTO’s Patent
Center.
Join us for a Rapid Response webinar focused on the new
USPTO Sequence Listing rules. Learn about the new process BEFORE it
goes into effect July 1. We will be joined by speakers from the USPTO
and WIPO, as well as experienced practitioners to provide guidance on
how to submit a compliant sequence listing in U.S. patent applications
and Patent Cooperation Treaty (PCT) applications.
Moderator: Carla Mouta-Bellum, Arrigo, Lee, Guttman & Mouta-Bellum, LLP, Washington, DC
Confirmed Speakers:
Kathleen Kalafus, USPTO
Hanna Kang, WIPO
Alice Martin, Barnes &Thornburg, LLP, Chicaog, IL - Chair, AIPLA Biotechnology Committee
Mary Till, USPTO
PRESENTATION SLIDES:
USPTO Sequence Listing Presentation
WIPO Sequence Listing Presentation
LINK TO RECORDING WILL BE POSTED HERE
News
-
AIPLA Submits Comments on the World Intellectual Property Organization Riyadh Design Law Treaty
June 24, 2026
Alexandria, VA. June 11, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the World Intellectual Property Organization Riyadh Design Law Treaty. -
.png?sfvrsn=143e8f56_1 "supreme court")
AIPLA Files Amicus Brief in Arbutus Biopharma Corp. v. Moderna, Inc.
June 22, 2026
Arlington, VA. June 5, 2026 – The American Intellectual Property Law Association (AIPLA) filed an amicus brief in Arbutus Biopharma Corp. v. Modernatx, Inc. -
Supreme Court Issues Unanimous Decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
June 4, 2026
On June 4, 2026, the Supreme Court issued a unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. While the Court reaffirmed existing law on pleading standards, it reversed the Federal Circuit’s decision that had focused on how relevant statements could be understood by medical providers as instructions to infringe. The amicus brief filed by AIPLA on March 27, 2026, advocated for affirmance and cautioned the Court not to change the patent infringement pleading standard or adopt any categorical exemption from inducement for a particular industry. -
AIPLA Views on H.R. 3269, the “ETHIC Act,” and H.R. 6485, the “Skinny Labels, Big Savings Act”
June 3, 2026
Arlington, VA. June 3, 2026 – The American Intellectual Property Law Association (AIPLA) submitted a letter to the House Judiciary Committee’s Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet outlining its views on H.R. 3269, the “ETHIC Act,” and H.R. 6485, the “Skinny Labels, Big Savings Act.” -
AIPLA Submits Comments to the USPTO on 2026 Supplemental GUI Guidance
May 15, 2026
Arlington, VA. May 12, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments to the USPTO on its Supplemental Guidance for Examination of Design Patent Applications Related to Computer-Generated Interfaces and Icons, issued on March 13, 2026.